Gábor Bedics retweeted
So many good reasons to consider @Hemasphere_EHA as the journal for your next #hematology study. Impact factor 11.9 is only one of the reasons...
#openaccess @EHA_Hematology
Gábor Bedics retweeted
Academic clinician–scientists risk becoming an endangered species.
World View from @StephenORahilly @Cambridge_Uni
nature.com/articles/s41591-0…
Our publication, which introduces "PersonALL", a conceptually novel, comprehensive copy number aberration-based risk assessment method in pediatric B-cell precursor Acute Lymphoblastic Leukemia, is out in @BrJCancer:
nature.com/articles/s41416-0……
@semmelweishu @CsabaBdr1
📷
Gábor Bedics retweeted
Delighted to share our new approach for high fidelity sc genotyping combined with scATAC - called GTAC! Do check it out! We love it. Great collaboration with the Hughes and Davies labs also in the WIMM. Credit to Sven, Asger, Angus and all co-authors.
cell.com/cell-stem-cell/full…
Gábor Bedics retweeted
What if we gave cancer a math test and refined treatment based on the score? Computational biologist @jiyang_yu created such a test. Discover how his work identifies cancers susceptible to a novel combination therapy in a clinical trial. bit.ly/Blog-Math-Test @NatureCancer
Gábor Bedics retweeted
⚠️Important awareness message.🪧
Saw this at #TimesSquare last night.
Know the symptoms & seek appropriate care.
Just last week, I saw 4 people from ages 26-39 in my🏥. All were stage-III or IV. Sometimes too late❗️
#CRCSM #ColorectalCancer📈
@preventcancer @OncoAlert #Cancer – at Manhattan, NY
Gábor Bedics retweeted
It is clear. If there is one thing we owe to patients, hemato-oncologists, pathologists, clinical trialists, scientists & regulators is to unify the CAC/ICC & WHO classification ASAP. Why wait for the next revision? #ASH22 inspiration
Gábor Bedics retweeted
Today #ASH22 session 803 on “New molecular tools for precision diagnostics” Jesus Gutierrez Abril from the lab will be presenting our heme WGTS pipeline. Single diagnostic workflow, 1 week turnaround, comparable sensitivity to SoC, additional findings of clinical relevance.
In our paper we report the first ROS1-rearranged non-Langerhans cell histiocytosis case in the literature, which was successfully treated with entrectinib. The study is just out in the prestigious Acta Neuropathologica.
link.springer.com/article/10…
2
It has been an honour to present our results regarding comprehensive genomic profiling of a real-world cohort of pediatric patients diagnosed with primary CNS tumors at the ESMO-MAP Conference in Amsterdam!
@myESMO @ESMO_Open @semmelweishu – at Amsterdam, The Netherlands
6
Gábor Bedics retweeted
Hooray! @BloodJournal accepted our manuscript on the largest comparison of minimal residual disease detection in ALL by qPCR and NGS. Once it's out, I'll post summary and link here. Till then we celebrate!🥳Thanks to first authors @svatonm and Aneta and my co-senior @FronkovaEva!
Gábor Bedics retweeted
📢Published today in @BloodJournal Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia | Blood | American Society of Hematology #hemepath #leusm #mdssm #mpnsm ashpublications.org/blood/ar…
Gábor Bedics retweeted
St. Jude is the first to supply a comprehensive view of the genomics of all subtypes of acute lymphoblastic leukemia. The study included samples from 2,574 pediatric ALL patients, the largest such cohort ever published. bit.ly/3RJkOdA @naturegenet
Gábor Bedics retweeted
‼️ PUBLISHED TODAY @NatureGenet
📰 The genomic landscape of pediatric acute lymphoblastic leukemia🩸🧬
🧑🤝🧑 @CMullighan Stephen P. Hunger, Jinghui Zhang, and team
👇🏾
go.nature.com/3q5TbPO
Gábor Bedics retweeted
Our important paper is finally out in @LeukemiaJnl ! Ph+ALL is not a single disease. While for "classical" Ph+ALL stemming from lymphoid lineage, MRD is predictive for outcome; for #CMLlike disease involving more lineages it is not. rdcu.be/cTtg1
Analysing copy number variation (CNV) can be tricky.
Introducing CNest; a new, freely available method for the analysis of CNV.
#embl
ebi.ac.uk/about/news/researc…
2
Gábor Bedics retweeted
Unified classification & risk stratification in AML. Trained & validated in 3,653 patients by @TaziYanis now published at: go.nature.com/3A6OXNS. Insights from this study adopted in ELN & WHO 2022.
Data & Code
Github:bit.ly/3QxGicw
Webtool: aml-risk-model.com/
Gábor Bedics retweeted
Interested to learn how new NGS technologies & biomarkers can improve diagnosis, treatments & outcomes?
Applications open for Molecular Pathology a d Diagnosis of cancer course @ConnectingSci @sangerinstitute
This Post is from an account that no longer exists. Learn more
